patient subgroup...
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mGC or mGEJC - L2 - all population, Ipilimumab (10 mg/kg) , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 1.54 [0.73, 3.26]< 1 0% 1 study (1/-) 12.8 % NA not evaluable crucial - progression or deaths (PFS) 1.59 [1.20, 2.10]< 1 0% 1 study (1/-) 0.1 % NA not evaluable important - irORR 0.24 [0.03, 2.19]> 1 0% 1 study (1/-) 10.3 % NA not evaluable non important - irPFS 1.44 [1.09, 1.91]< 1 0% 1 study (1/-) 0.5 % NA not evaluable non important - safety endpoints 00 TRAE (any grade) 2.05 [0.90, 4.67]< 1 0% 1 study (1/-) 4.4 % NA not evaluable non important - TRAE (grade 3-4) 3.03 [0.91, 10.04]< 1 0% 1 study (1/-) 3.5 % NA not evaluable non important - TRAE leading to death (grade 5) 1.92 [0.55, 6.70]< 1 0% 1 study (1/-) 15.3 % NA not evaluable non important - TRAE leading to discontinuation (any grade) 1.00 [0.02, 51.28]< 1 0% 1 study (1/-) 50.0 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Asthenia TRAE (grade 3-4) 1.59 [0.05, 48.47]< 1 0% 1 study (1/-) 39.7 % NA not evaluable non important - Colitis TRAE (grade 3-4) 4.94 [0.24, 101.33]< 1 0% 1 study (1/-) 15.3 % NA not evaluable non important - Decreased appetite TRAE (grade 3-4) 1.59 [0.05, 48.47]< 1 0% 1 study (1/-) 39.7 % NA not evaluable non important - Diarrhoea TRAE (grade 3-4) 8.56 [0.45, 161.00]< 1 0% 1 study (1/-) 7.8 % NA not evaluable non important - Endocrine disorders TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important - Fatigue TRAE (grade 3-4) 3.24 [0.14, 73.60]< 1 0% 1 study (1/-) 23.3 % NA not evaluable non important - Hypothyroidism TRAE (grade 3-4) 3.24 [0.14, 73.60]< 1 0% 1 study (1/-) 23.3 % NA not evaluable non important - Myalgia TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important - Nausea TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important - Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) 0.19 [0.01, 4.33]< 1 0% 1 study (1/-) 84.8 % NA not evaluable non important - Peripheral neuropathy TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important - Pruritus TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important - Rash TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important - Vomiting TRAE (grade 3-4) 0.79 [0.02, 40.48]< 1 0% 1 study (1/-) 54.6 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.